In the phase 3 trial, nemolizumab monotherapy showed rapid and sustained improvements in key signs (skin lesions) and ...

The table below is a review of notable updates that occurred in November 2024 for investigational products in development (not an inclusive list). Click on the status to view our full coverage. The ...

Preclinical studies showed that the addition of IL-15 could improve the performance of CAR T cell-based immunotherapies.

The study reveals IL-15's role in enhancing GPC3 CAR T cell therapy, improving tumor targeting and T cell survival in ...

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that the U.S. Food and Drug Administration (FDA) has ...

CAN10 is designed to inhibit the pro-inflammatory cytokines through its action on the interleukin-1 receptor accessory ...

Researchers report results of the first-in-human phase 1 clinical trials of a novel immunotherapy approach for solid tumors ...